Sparks commentary - QBiotics

Healthcare

Sparks - QBiotics

More on this equity
QBiotics launches capital raise
Published by Arron Aatkar, PhD

QBiotics has launched a new capital raise targeting up to A$40m, with a minimum raise of A$5m, through an offer of new shares priced at A$0.55 each; a replacement prospectus was lodged with the Australian Securities and Investments Commission on 12 August 2026. The raise is intended to provide working capital to advance QBiotics’ clinical-stage pipeline and support its next phase of growth, including development of its lead oncology asset, tigilanol tiglate. QBiotics has also announced investor briefings in Melbourne, Sydney, Brisbane and Cairns from 24–27 August, where management will outline the company’s progress and the objectives of the proposed capital raising.

Edison’s valuation report on QBiotics (published 12 May 2026) can be accessed here.

Cookie Policy Overview
Edison Group

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping us understand which section of the website you find more interesting and useful. See our Cookie Policy for more information.

Strictly necessary and functional

These cookies are used to deliver our website and content. Strictly necessary cookies relate to our hosting environment, and functional cookies are used to facilitate social logins, social sharing and rich-media content embeds.

Advertising

Advertising Cookies collect information about your browsing habits such as the pages you visit and links you follow. These audience insights are used to make our website more relevant.

Performance

Performance Cookies collect anonymous information designed to help us improve the site and respond to the needs of our audiences. We use this information to make our site faster, more relevant and improve the navigation for all users.